RT @RapidResponseHQ: Where others see an impossible problem, @costplusdrugs CEO @alexosh sees an opportunity to expose predatory health ins…

@UnpopularPharm @tjparker O, we are very open that we work with a number of transparent PBMs: . To me, nothing wrong with PBMs acting as a payment processor. Problem is when the big 3 take 30% of all pharma revenue as their fee in one way or another which is nuts.

@tjparker @UnpopularPharm If there are better ideas for how help individual patients while helping indy pharmacies and providers while saving the system as a whole money, we are totally open to it! Our strategy now is the best we could create with all the information we currently have.

@UnpopularPharm @tjparker I mean, it's kind of an apocalyptic year for indy pharmacies as it is. We are doing the best we can to help patients and pharmacies with the data and analytics we have. Trust me, we aren't making TJ money out of this 😂. Always open to ideas though!

@UnpopularPharm @tjparker Our $12 dispense fee is what is recommended by NCPA. If you run an independent pharmacy, you can buy at our price here:

@UnpopularPharm @tjparker Our hypothesis is that indy pharmacies will actually make more money with just a flat markup on all drugs. Yes, atorvastatin and other common drugs become more expensive, but the savings on expensive drugs makes up for it. Pharmacy makes more, payers pay less. PBM loses.

@UnpopularPharm @tjparker Correct. Pharmacies, acute care facilities / hospitals can sign up to get access to our pricing here:

@tjparker @UnpopularPharm Cool, I look forward to seeing whether an analysis by the former head of Amazon Pharmacy shows they have better pricing than us. 😂 Be well TJ. Enjoy the buyout funds!

@tjparker @UnpopularPharm The last study I linked as well as several others look at all generic generic drugs. Do you have any data to the contrary other than a secret internal analysis from two years ago? Would be helpful to know if there is any contradictory data.

@tjparker @UnpopularPharm Another from several researchers and Harvard, Cleveland Clinic, MIT, TJU, and UPenn from a few days ago:

@tjparker @UnpopularPharm Data from a research group at Vanderbuilt

@tjparker @UnpopularPharm Another comparison to Medicare broadly nationwide @A_Ciaccia

@tjparker @UnpopularPharm An example study that compares our pricing to that paid by Washington state. @A_Ciaccia

@tjparker @UnpopularPharm Everything included

@tjparker @UnpopularPharm That’s way, way off. We are at least at AWP -91%. Several external academic groups and consultancies (see 3Axis) have validated that, and we have a fair amount of payer business now for that reason. Again, any data you can link to that shows us being more expensive in aggregate?

@tjparker @UnpopularPharm Do you have a source for that statement TJ? Our internal analytics show a 50-60% savings for payers with our model while being more profitable for pharmacies. AWP is an arbitrage shell game for big PBMs.

RT @mcuban: The PBM Smackening is happening !